Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAGE-421
- Development stage
- Preclinical
- Lead developer
- Sage Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAGE-421 is an investigational **oral small molecule drug** that acts as a **positive allosteric modulator (PAM) of the NMDA receptor**. It is being developed by Sage Therapeutics for potential use in **neurodevelopmental disorders** and for **cognitive recovery and rehabilitation**, targeting CNS conditions where NMDA receptor modulation may be beneficial[1][6]. The drug is currently at the preclinical development stage[1][5][6].
- Brand names
- SAGE-421SAGE421SAGE 421
- Other names
- SAGE-421SAGE421SAGE 421
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on SAGE-421.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAGE-421.